Natera, Inc. $NTRA Shares Purchased by Groupama Asset Managment

Groupama Asset Managment lifted its stake in Natera, Inc. (NASDAQ:NTRA) by 3.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 95,061 shares of the medical research company’s stock after purchasing an additional 2,805 shares during the quarter. Groupama Asset Managment owned about 0.07% of Natera worth $19,011,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Integrated Wealth Concepts LLC increased its stake in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Natera during the second quarter worth $298,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Natera during the second quarter valued at $558,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total value of $818,700.00. Following the sale, the insider directly owned 134,643 shares of the company’s stock, valued at approximately $36,744,074.70. This represents a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 173,951 shares of company stock valued at $39,412,294 over the last ninety days. Corporate insiders own 5.05% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $267.76 on Friday. The firm has a market capitalization of $38.35 billion, a P/E ratio of -164.27 and a beta of 1.51. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04. The company’s fifty day moving average price is $246.77 and its 200-day moving average price is $222.22.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research reports. Sanford C. Bernstein started coverage on Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price on the stock. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Natera in a research report on Monday, July 6th. The Goldman Sachs Group assumed coverage on Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 price target on the stock. BTIG Research set a $275.00 price objective on Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. Finally, Royal Bank Of Canada initiated coverage on Natera in a research note on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $267.83.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.